From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands.(2008-07時点)
